Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Sodium Valproate I.P. 133mg + Valproic Acid I.P. 58mg (C.R.)
Therapeutic Category
General and OTC medicines, Neurology, Antiepileptic
Dosage Form
Tablet
Packaging Type
Strip Pack
Packaging
10*10
Price
₹156/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Valpotime CR 200 is a controlled-release formulation containing a combination of Sodium Valproate (133mg) and Valproic Acid (58mg). This medication is primarily used for the treatment of epilepsy and bipolar disorder, offering long-lasting therapeutic effects with reduced frequency of dosing. The controlled-release mechanism ensures a steady and gradual release of the active ingredients, which helps in maintaining a consistent blood level of the drug, improving efficacy, and minimizing side effects.
Valpotime CR 200 works by stabilizing electrical activity in the brain, which is particularly helpful for managing seizures. It also helps in regulating mood swings associated with bipolar disorder, reducing the frequency and severity of manic episodes. The dual action of Sodium Valproate and Valproic Acid makes this medication effective in controlling both generalized and focal seizures and supporting long-term mental health stability.
This medication is typically prescribed for individuals suffering from epilepsy, seizure disorders, or bipolar disorder. The controlled-release formulation helps reduce the risk of side effects by maintaining steady drug levels, improving patient compliance and quality of life.
Common side effects include nausea, dizziness, weight gain, tremors, and drowsiness. Serious side effects may include liver toxicity, pancreatitis, or blood disorders. Contact a healthcare provider if unusual symptoms occur.
For the treatment of epilepsy, including generalized and focal seizures, and the management of bipolar disorder.
Consult a healthcare provider before use if pregnant, breastfeeding, or if you have liver disease. Regular blood tests may be required to monitor liver function.
Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.
Composition : Sodium Valproate 200mg + Valproic Acid 87mg
Composition : Sodium Valproate (333mg) + Valproic Acid (145mg) Tablet
Composition : Piracetam I.P. 500mg Syrup
Composition : Piracetam (200mg)
Composition : Piracetam (800mg) Tablet
Composition : Betahistine 16mg + Piracetam 400mg + Vinpocetine 5mg + Excipients q.s. tablet
Composition : Alpha Lipoic Acid (100mg) + Folic Acid (1.5mg) + Methylcobalamin (1500mcg) + Pregabalin (75mg) + Vitamin B6 (Pyridoxine) (3mg)
Composition : Pregabalin (75mg) + Nortriptyline (10mg) + Methylcobalamin (1500mcg) + Vitamin D3 (2000IU)
Composition : Pregabalin (75mg) + Nortriptyline (10mg)
Composition : Pregabalin (75mg) + Etoricoxib (60mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Sodium Valproate + Valproic Acid CR Tablet is an antiepileptic (anti-seizure) and mood-stabilizing medication used for the management of epilepsy, generalized and partial seizures, bipolar disorder, and migraine prophylaxis. The controlled-release (CR) formulation provides stable blood levels over time, improved patient compliance, and reduced dosing frequency, making it an important product in the neurology and psychiatric care segment.
Medical distributors and wholesalers can benefit from consistent demand from neurologists, psychiatrists, and general physicians. Neurological and psychiatric disorders require long-term or lifelong therapy, ensuring regular prescriptions, repeat purchases, and stable market demand.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in neurology, psychiatry, and chronic care segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high chronic therapy adherence, strong specialist-driven prescriptions, and long-term treatment requirements, making it a stable, high-value, and repeat-prescription pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in neurology and psychiatric formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the neurological and mental health segment.